Medicine prices in Pakistan have been consistently increasing since the government decided to deregulate the pharmaceutical sector. This decision, intended to stabilize the industry and improve drug availability, has instead led to a substantial financial burden on the public.
Read More: Diabetic Kidney Disease: A Growing Health Crisis in Pakistan
The deregulation policy allowed pharmaceutical companies greater freedom in setting prices, with minimal oversight from regulatory bodies. As a result, the cost of essential medicines, including life-saving drugs, has surged, making healthcare increasingly inaccessible for low- and middle-income families.
Healthcare experts warn that this unchecked rise in medicine prices could lead to a public health crisis, as many individuals may forego necessary treatments due to financial constraints. Patients suffering from chronic conditions like diabetes, heart disease, and cancer are particularly affected, as their reliance on costly, long-term medication grows.
Consumer advocacy groups have called on the government to revisit its deregulation policies and establish a balance between industry sustainability and public welfare. They argue for stricter price controls, increased transparency in the pharmaceutical sector, and policies to ensure affordability for essential medications.
While pharmaceutical companies cite rising production costs, inflation, and currency depreciation as reasons for the price hikes, critics argue that profit-driven motives are overshadowing the need for accessible healthcare.
The ongoing situation highlights the need for robust government intervention to regulate medicine prices and prioritize public health over corporate interests. Citizens are calling for immediate action to address the spiraling costs and ensure affordable access to essential medications for all.
